ARKD-104 / Arkuda Therap - LARVOL DELTA

ARKD-104, A Potential Treatment of Frontotemporal Dementia and Other Neurodegenerative Disorders (AAIC 2023) - "ARKD-104 has excellent CNS drug-like properties, increases PGRN in the CNS of non-human primates and increases important cofactors of lysosomal enzymes, . ARKD-104 is therefore a promising candidate for continued development as a treatment for FTD- GRN , Parkinson’s disease and other neurodegenerative disorders exhibiting lysosomal dysfunction."

Alzheimer's Disease • CNS Disorders • Dementia • Frontotemporal Lobar Degeneration • Movement Disorders • Parkinson's Disease

Arkuda Therapeutics to Present Update on ARKD-104, its First-in-Class Oral Development Candidate for the Treatment of Frontotemporal Dementia and other Neurodegenerative Disorders at the Alzheimer's Association International Conference 2023 (PRNewswire) - "Arkuda Therapeutics...will present pre-clinical data on lead development candidate ARKD-104 for the treatment of GRN-related frontotemporal dementia (FTD-GRN) at the 2023 Alzheimer's Association International Conference (Poster P1-752)....Data presented demonstrate that ARKD-104, a novel, brain-penetrant, orally bioavailable small molecule, increases PGRN in the central nervous system (CNS) of non-human primates in a dose-dependent manner, and that the increase in PGRN levels is sustained with daily repeat dosing which returned to baseline following cessation of treatment. Further, ARKD-104 was shown to increase important cofactors of lysosomal enzymes important to neuronal function....Arkuda is currently conducting IND-enabling studies for ARKD-104 and expects to initiate a first-in-human trial starting in the first half of 2024."

New P1 trial • Preclinical • CNS Disorders • Dementia